Biogen Idec (BIIB) reported third quarter 2014 earnings per share of $3.79 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $3.22 and the year-ago earnings of $2.34 per share. Third quarter 2014 revenues increased 37% to $2.5 billion, topping the Consensus Estimate of $2.4 billion. Including one-time items, third quarter 2014 earnings increased 77% to $3.62 per share. Third quarter … Continue reading Top Biotech Stock News: Biogen’s Q3 Earnings Top Estimates

Amgen (AMGN) reported third quarter 2014 earnings of $2.30 per share, well above the Consensus Estimate of $2.06 and the year-ago earnings of $1.93. Earnings were driven by higher revenues and higher profitability on Enbrel. Total revenues increased 6% to $5,031 million in the third quarter of 2014, beating the Consensus Estimate of $4,918 million. Including one-time items, third quarter earnings declined 10% to $1.61 … Continue reading Biotech Stock News: Amgen Looks Upbeat, Beats on Q3 Earnings & Revenues

Alexion Pharmaceuticals’ (ALXN) third-quarter 2014 earnings (including stock-based compensation expense) of $1.14 per share beat the Zacks Consensus Estimate by 9 cents. The earnings beat was attributable to higher-than-expected revenues. Moreover, earnings were above the year-ago figure by 56.2%. Including one-time items, Alexion’s earnings climbed 87% year over year to 88 cents per share in the reported quarter. Alexion’s revenues climbed 39% year over year … Continue reading Biotech Stock in News: Alexion Beats on Earnings & Revenues in Q3

Celgene Corporation (CELG) reported third-quarter 2014 earnings of 88 cents per share (including stock-based compensation expenses), which surpassed the Zacks Consensus Estimate by 6 cents. The company’s earnings were $1.39 per share in the year-ago quarter. We note that figures have been adjusted to reflect the two-for-one stock split effected earlier in the year. Total revenues climbed 18% year over year to $1.98 billion in … Continue reading Biotech Stock News: Celgene Beats Q3 Earnings Estimates

Gilead Sciences (GILD) has been a leader in the resurgent Biotech group. Gilead recovered from the steep drop in the Biotech group in March and April and has been outperforming the group and the overall market since mid-May. With GILD leading the Biotech stocks to new highs, all eyes will be on their earnings report due out this week. Gilead gave us a clue to … Continue reading Biotech Stock To Buy Now: Gilead Sciences (GILD)

Harvoni is the new tablet launched this month by Gilead Sciences, Inc (NASDAQ GILD) which Stewart acquired first because she take part in its clinical trials. Harvoni is a mixture of the novel drug ledipasvir and sofosbuvir, which for closely a year has been sold only under the brand name Sovaldi. Sovaldi’s launch shattered all earlier new drug launches. Since it came out in December … Continue reading Biotech News: A Look At The Most Active Biotech Stocks In The Market